Otolaryngol Head Neck Surg:布地奈德与盐水洗鼻在过敏性鼻炎治疗中的比较

2020-05-29 AlexYang MedSci原创

布地奈德鼻洗目前广泛的应用于慢性鼻窦炎的治疗,尤其是在内镜鼻窦手术后用于改善对炎症的控制,而其在过敏性鼻炎中的治疗还未有研究。最近,有研究人员评估了过敏性鼻炎(AR)患者对布地奈德缓冲高渗盐水鼻腔冲洗

布地奈德鼻洗目前广泛的应用于慢性鼻窦炎的治疗,尤其是在内镜鼻窦手术后用于改善对炎症的控制,而其在过敏性鼻炎中的治疗还未有研究。最近,有研究人员评估了过敏性鼻炎(AR)患者对布地奈德缓冲高渗盐水鼻腔冲洗和高渗盐水鼻腔冲洗对的主观和临床反应。

研究是一个前瞻性的、单中心、双盲和随机安慰剂对照试验。研究包括了52名AR患者,并随机分配到2个小组,分别接受布地奈德缓冲高渗盐水鼻腔冲洗和高渗盐水鼻腔冲洗。研究人员在基线点和治疗4周后进行了SNOT、VAS和临床评估。研究发现,SNOT-22、VAS和修正后Lund-Kennedy得分在两个小组中均有改善(p<0.001)。布地奈德缓冲高渗盐水鼻腔冲洗组的SNOT-22评分(p=0.012)和VAS评分(p=0.007)要比盐水鼻腔冲洗组显著更好。然而,临床响应在2个小组之间没有显著的差异(p=0.268)。

最后,研究人员指出,他们的研究为盐水洗鼻治疗过敏性鼻炎增加了证据,但是同时也阐释了添加布地奈德后的洗鼻效果。因此,布地奈德鼻洗也是过敏性鼻炎治疗的一种可行方法。

原始出处:

Nikitha Periasamy , Kailesh Pujary , Ajay M Bhandarkar et al. Budesonide vs Saline Nasal Irrigation in Allergic Rhinitis: A Randomized Placebo-Controlled Trial. Otolaryngol Head Neck Surg. 12 May 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047260, encodeId=fac1204e26087, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jul 19 01:15:23 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081001, encodeId=e86a208100135, content=<a href='/topic/show?id=0b79e22705f' target=_blank style='color:#2F92EE;'>#盐水洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72270, encryptionId=0b79e22705f, topicName=盐水洗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Wed May 05 11:15:23 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044136, encodeId=d787204413688, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 24 17:15:23 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948370, encodeId=682c19483e08c, content=<a href='/topic/show?id=a2e9e227142' target=_blank style='color:#2F92EE;'>#盐水洗鼻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72271, encryptionId=a2e9e227142, topicName=盐水洗鼻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Jan 26 19:15:23 CST 2021, time=2021-01-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047260, encodeId=fac1204e26087, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jul 19 01:15:23 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081001, encodeId=e86a208100135, content=<a href='/topic/show?id=0b79e22705f' target=_blank style='color:#2F92EE;'>#盐水洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72270, encryptionId=0b79e22705f, topicName=盐水洗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Wed May 05 11:15:23 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044136, encodeId=d787204413688, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 24 17:15:23 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948370, encodeId=682c19483e08c, content=<a href='/topic/show?id=a2e9e227142' target=_blank style='color:#2F92EE;'>#盐水洗鼻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72271, encryptionId=a2e9e227142, topicName=盐水洗鼻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Jan 26 19:15:23 CST 2021, time=2021-01-26, status=1, ipAttribution=)]
    2021-05-05 TZF0804
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047260, encodeId=fac1204e26087, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jul 19 01:15:23 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081001, encodeId=e86a208100135, content=<a href='/topic/show?id=0b79e22705f' target=_blank style='color:#2F92EE;'>#盐水洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72270, encryptionId=0b79e22705f, topicName=盐水洗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Wed May 05 11:15:23 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044136, encodeId=d787204413688, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 24 17:15:23 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948370, encodeId=682c19483e08c, content=<a href='/topic/show?id=a2e9e227142' target=_blank style='color:#2F92EE;'>#盐水洗鼻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72271, encryptionId=a2e9e227142, topicName=盐水洗鼻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Jan 26 19:15:23 CST 2021, time=2021-01-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047260, encodeId=fac1204e26087, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jul 19 01:15:23 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081001, encodeId=e86a208100135, content=<a href='/topic/show?id=0b79e22705f' target=_blank style='color:#2F92EE;'>#盐水洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72270, encryptionId=0b79e22705f, topicName=盐水洗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Wed May 05 11:15:23 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044136, encodeId=d787204413688, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 24 17:15:23 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948370, encodeId=682c19483e08c, content=<a href='/topic/show?id=a2e9e227142' target=_blank style='color:#2F92EE;'>#盐水洗鼻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72271, encryptionId=a2e9e227142, topicName=盐水洗鼻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Jan 26 19:15:23 CST 2021, time=2021-01-26, status=1, ipAttribution=)]

相关资讯

N Engl J Med:奥拉帕尼治疗转移去势抵抗性前列腺癌研究

在前列腺癌和其他癌症患者中,与DNA修复(包括同源重组修复)有关基因的多个基因功能丧失变异与聚(二磷酸腺苷-核糖)聚合酶(PARP)抑制剂响应相关。

Eur Urol:恩杂鲁胺雄激素阻断治疗联用对转移激素敏感性前列腺癌患者健康相关生活质量影响研究

ARCHES研究中的转移激素敏感性前列腺癌(mHSPC)中,与单独的ADT治疗相比,恩杂鲁胺与雄激素阻断治疗(ADT)联用能够改善影像学无进展生存(rPFS)。最近,有研究人员评估了长达73周的患者报

盘点:过敏性鼻炎与治疗

【1】Front Pharmacol:大籽蒿花粉过敏性鼻炎1年皮下免疫治疗临床效果评估

“领跑者”上海质子重离子医院:5年治疗出院2692例患者

四年半前,64岁的张先生罹患高危局限期前列腺癌,来院治疗前,他曾因其它泌尿系统疾病做过大手术,不愿再次“大动干戈”的张先生选择在上海市质子重离子医院接受前列腺癌重离子治疗。随访

盘点:听力障碍与治疗

【1】Laryngoscope :辅助治疗偏头痛的药物在突发感官听力损失中的治疗

盘点:前列腺癌与治疗

【1】Nat Commun:前列腺特异性抗原动态能够预测个体对间歇性雄激素阻断治疗的个体响应